Sidney Kimmel Comprehensive Cancer Center

Researchers

• DLDung T Le

Running trials

• Not yet recruiting

  Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

  NCT07793253· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Not yet recruiting

  The Canopy Cancer Collective Clinical Registry Protocol

  NCT07605702· Canopy Cancer Collective, LLC· Source

• Recruiting

  NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

  NCT06941857· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

  NCT06411691· Phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

  NCT06638307· Phase 1· Stemline Therapeutics, Inc.· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Summit Therapeutics· Source

• Recruiting

  A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

  NCT05440708· Phase 1/2· Tvardi Therapeutics, Incorporated· Source

• Active, not recruiting

  Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

  NCT05013216· Phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Active, not recruiting

  Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma

  NCT04658147· Phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source

• Recruiting

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source

• Active, not recruiting

  Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

  NCT04117087· Phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Active, not recruiting

  Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

  NCT04093167· Phase 2/3· Canadian Cancer Trials Group· Source

• Recruiting

  DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

  NCT04248569· Phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  NCT02422641· Phase 2· Wake Forest University Health Sciences· Source

• Active, not recruiting

  Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

  NCT01436968· Phase 3· Candel Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer3 recruiting
• Pancreatic cancer3 recruiting
• Colorectal cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Childhood cancers1 recruiting
• Lung cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

  NCT05014776· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

  NCT04997902· Phase 1/2· Kura Oncology, Inc.· Source

• Completed

  Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

  NCT04753879· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

  NCT04301778· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Withdrawn

  Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

  NCT04331717· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

  NCT03914794· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

  NCT04209686· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

  NCT04116073· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

  NCT03767582· Phase 1/2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

  NCT03638141· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

  NCT03727880· Phase 2· Lei Zheng· Source

• Completed

  Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

  NCT03642067· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

  NCT03711058· Phase 1/2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

  NCT03578367· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

  NCT03106779· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

  NCT01592370· Phase 1/2· Bristol-Myers Squibb· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer61 works · 2 trials
• Pancreatic cancer48 works · 10 trials
• Acute myeloid leukaemia31 works · 0 trials
• Myelodysplastic syndromes24 works · 0 trials
• Metastatic breast cancer14 works · 2 trials
• Myeloproliferative neoplasms7 works · 1 trial
• Aplastic anaemia4 works · 0 trials